β-Klotho Gene Linked to Muscle Invasion and Poor PFS in Bladder Cancer
The gene known as β-Klotho (KLβ) appears to play an important role in tumor invasion and progression in patients with bladder cancer, and urine KLβ levels may act as a useful biomarker, according to a new study.
Non-Urothelial Bladder Cancer Often Upstaged During Surgery
Patients with non-urothelial bladder cancer are more commonly upstaged during surgery compared with urothelial cancers.
Mutation Pattern May Help Predict Treatment Response in Urothelial Carcinoma of the Bladder
A small genomic study of patients with chemoradiation-treated urothelial carcinoma of the bladder found similar mutation patterns between primary and recurrent tumors.
Urine-Based DNA Test Can Help Diagnose Bladder Tumors
A novel urine-based DNA test was effective at detecting bladder cancer, and in particular at identifying patients with gross hematuria who do not require cystoscopy.
Push for Molecular Profiling Could Transform Advanced Bladder Cancer Care
New NCCN guidelines regarding genomic profiling will likely yield important opportunities to improve the care of patients with advanced bladder cancer.
Considering Neoadjuvant Chemotherapy Options in Bladder Cancer
In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.
POINT: Is Immediate Radical Cystectomy Justified When Non–Muscle-Invasive Bladder Cancer First Presents as High-Grade T1 Urothelial Carcinoma on Re-Resection?
After a thorough repeat TURBT, disease control can be achieved with intravesical BCG and a bladder-sparing approach.
First-Line Atezolizumab Effective in Cisplatin-Ineligible Urothelial Cancer
Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.
By clicking Accept, you agree to become a member of the UBM Medica Community.